Private Advisor Group’s Accelerate Diagnostics AXDX Stock Holding History

Private Advisor Group’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10	Closed	-$2K	–	1716
2020 Q2	$2K	Buy	+10	New	+$986	﹤0.01%	3539

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAM

Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Private Advisor Group's AXDX Position: Q3 2020 in Review

Private Advisor Group sold out of Accelerate Diagnostics (AXDX) in Q3 2020, closing a stake of 10 shares — an estimated $2K sold.

Private Advisor Group first reported a position in AXDX in Q2 2020 and held it in 1 quarter. The position peaked at $2K in Q2 2020. 112 funds tracked by Wall St. Rank hold AXDX as of Q3 2020.

Private Advisor Group reported no remaining Accelerate Diagnostics position as of Q3 2020 after selling out during the quarter.
Private Advisor Group sold 10 Accelerate Diagnostics shares in Q3 2020, an estimated $2K.
Private Advisor Group first reported a position in Accelerate Diagnostics in Q2 2020 and held it in 1 quarter.
Private Advisor Group's Accelerate Diagnostics position peaked at $2K in Q2 2020.
112 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.